News (211)

Transcript : Guardant Health, Inc., Q1 2024 Earnings Call, May 09, 2024
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance BU
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone BU
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting BU
Guardant Health - Royal Marsden And Guardant Health Partnership Provides State-of-the-art Blood Test To Benefit Lung Cancer Patients In Expanded NHS Study AQ
Transcript : Guardant Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook BU
Guardant Health Announces Preliminary Fourth Quarterand Full Year 2023 Results AQ
Transcript : Guardant Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results BU
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer BU
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford BU
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities BU
Guardant Health to Appeal Federal District Court Verdict BU
Transcript : Guardant Health, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance BU
Transcript : Guardant Health, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 11:20 AM
GUARDANT HEALTH RECEIVES COVERAGE FOR GUARDANT REVEAL FROM GEISINGER HEALTH PLAN AQ
Transcript : Guardant Health, Inc. - Analyst/Investor Day
GUARDANT HEALTH RECEIVES REGULATORY APPROVAL IN JAPAN FOR GUARDANT360 CDX AS COMPANION DIAGNOSTIC TO ENHERTU FOR TREATMENT OF NON-SMALL CELL LUNG CANCER PATIENTS WITH HER2 MUTATIONS AQ
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan BU
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations BU
Transcript : Guardant Health, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance BU
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana BU
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan BU
Transcript : Guardant Health, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 04:00 PM
Transcript : Guardant Health, Inc. Presents at The 43rd Annual William Blair Growth Stock Conference, Jun-06-2023 04:40 PM
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting BU
Guardant Health Secures Coverage from Major US Commercial Health Insurers for Guardant360 Blood Test for Comprehensive Genomic Profiling AQ
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling BU
Guardant Health Releases Inaugural ESG Report BU
Transcript : Guardant Health, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 02:20 PM
Transcript : Guardant Health, Inc., Q1 2023 Earnings Call, May 09, 2023
Guardant Health Reports First Quarter 2023 Financial Results BU
Guardant Health Announces Additions to Leadership Team BU
Guardant Health and Parker Institute for Cancer Immunotherapy launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response AQ
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response BU
Guardant Health Receives Medicare Coverage for Guardant360 Response to Monitor Cancer Patient Response to Immunotherapy AQ
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy BU
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting BU
Transcript : Guardant Health, Inc. Presents at Cowen 43rd Annual Healthcare Conference, Mar-08-2023 10:30 AM
Musa Tariq Joins Guardant Health Board of Directors BU
Transcript : Guardant Health, Inc., Q4 2022 Earnings Call, Feb 23, 2023
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook BU
1234NextSee all

Insiders

Picture Helmy Eltoukhy
Helmy Eltoukhy

Founder of Guardant Health, Inc. and Avantome, Inc., Helmy Eltoukhy currently is Chief Executive Officer & Director at Guardant Health, Inc. He previously occupied the position of Director-Advanced Technology Research at Illumina, Inc. and President & Chief Executive Officer of Avantome, Inc. (a subsidiary of Illumina, Inc.) and Principal at Stanford Genome Technology Center. Dr. Eltoukhy received an undergraduate degree, a doctorate and a graduate degree from Stanford University.


Picture Adam Eltoukhy
Adam Eltoukhy

Adam Eltoukhy is currently the Director at Samsara Networks Ltd.
and also holds the position of Secretary, Chief Legal Officer & Executive VP at Samsara, Inc. Previously, he worked as Legal Counsel at Palantir Technologies, Inc. from 2012 to 2018.
He also has experience as an Associate at Morrison & Foerster LLP and Weil, Gotshal & Manges LLP.
Mr. Eltoukhy completed his undergraduate degree at Santa Clara University and his graduate degree at Stanford Law School.


Picture Eddie Eltoukhy
Eddie Eltoukhy

Eddie Eltoukhy is currently a Partner at Pear Ventures Management LLC.
He holds an MBA from Stanford University.


Picture Shafy Eltoukhy
Shafy Eltoukhy

Shafy Eltoukhy is currently the Chief Executive Officer at Open-Silicon, Inc. and the Senior Vice President & General Manager at SiFive, Inc. Previously, he held positions such as Director-Technology Development at Microsemi SoC Corp., Principal at Intel Corp., Vice President-Operations & Technology Development at Open-Silicon, Inc., Faculty Member at The University of Waterloo, Vice President-Technology at Lightspeed Logic, Inc., and Faculty Member at the University of Cairo.
He holds a doctorate degree from The University of Waterloo and undergraduate and graduate degrees from the University of Cairo.


Picture Youssri Helmy
Youssri Helmy

Youssri Helmy was the founder of ITWorx Egypt SAE (1994), ITWorx, Inc. (1994), IdealRatings, Inc. (2006), and Eonite Perception, Inc. (2015) where he held the titles of Chief Executive Officer and Chairman.
Mr. Helmy is also the founder of Swan Labs Corp.
He currently holds the position of Director at SilMinds LLC and Endeavor Egypt.
Mr. Helmy received an undergraduate degree from the University of Cairo.



Picture Ahmed Helmy
Ahmed Helmy

Ahmed Helmy has a current job as the Head of Sales & Trading at Jazira Securities Brokerage.



Picture Helmy Said
Helmy Said

Helmy Said worked as a Director of Human Resources & General Affairs at PT Elnusa Tbk and as a Manager of System, Method & Productivity at PT Pertamina (Persero).
He graduated from the University of Indonesia in 1998 and received his undergraduate degree from Sriwijaya University in 1984.


No results for this search

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW